

Quinazoline derivatives.Patent Number: EP0602851, B1

Publication date: 1994-06-22

Inventor(s): BARKER ANDREW JOHN (GB); BROWN DEARG SUTHERLAND (GB)

Applicant(s):: ZENECA LTD (GB)

Requested Patent: US5580870

Application Number: EP19930309680 19931203

Priority Number (s): GB19920025765 19921210; GB19930010248 19930518

IPC Classification: C07D403/12 ; C07D409/12 ; C07D239/94 ; C07D417/12 ; C07D403/14 ; C07D491/056 ; A61K31/505

EC Classification: C07D239/94, C07D401/12, C07D403/12, C07D417/12, C07D491/04

Equivalents: AU5072893, AU664496, CA2103383, CN1094043, CZ9302651, DE69305310D, DE69305310T, ES2093367T, FI935431, GR3021326T, HU65622, IL107678,
 JP6336481, NO304487B, NO934504, NZ250218

Abstract

The invention concerns quinazoline derivatives of the formula I wherein m is 1, 2 or 3 and each R<1> includes hydroxy, amino, ureido, hydroxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy and (1-3C) alkyleneoxy; and Q is a 9- or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, or Q is a 9- or 10-membered bicyclic aryl moiety which heterocyclic or aryl moiety may optionally bear one or two substituents selected from halogeno, hydroxy, oxo, amino, nitro, carbamoyl, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylamino, di-[(1-4C)alkyl]amino and (2-4C)alkanoylamino; or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compositions containing them; and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of cancer.

Data supplied from the esp@cenet database - I2

- Please see exhibit 12 -